Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schuler

Showing results (241-250 of 251) with videos related to

Pageof 26
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2019
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyO Türeci, U Sahin, H Schulze-Bergkamen, et al.
Journal of Cancer Research and Clinical Oncology|November 5, 2022
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinomaM Maßmann, J Treckmann, P Markus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialM Schuler, J C-H Yang, K Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsJ C-H Yang, L V Sequist, C Zhou, et al.
ESMO Open|July 17, 2024
Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivityI-A Mavroeidi, J Burghofer, S Kalbourtzis, et al.
ESMO Open|January 9, 2024
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter studyJ Keyl, A Bucher, F Jungmann, et al.
Journal of Clinical Microbiology|April 4, 2000
Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzerG T Maine, R Stricker, M Schuler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)N Frost, M Joosten, J Franzen, et al.
Journal of Child Neurology|March 21, 2012
Consensus statement on standard of care for congenital myopathiesChing H Wang, James J Dowling, Kathryn North, et al.
Journal of Child Neurology|November 17, 2010
Consensus statement on standard of care for congenital muscular dystrophiesChing H Wang, Carsten G Bonnemann, Anne Rutkowski, et al.
Pageof 26

Showing results (241-250 of 251) with videos related to

Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2019
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyO Türeci, U Sahin, H Schulze-Bergkamen, et al.
Journal of Cancer Research and Clinical Oncology|November 5, 2022
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinomaM Maßmann, J Treckmann, P Markus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialM Schuler, J C-H Yang, K Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsJ C-H Yang, L V Sequist, C Zhou, et al.
ESMO Open|July 17, 2024
Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivityI-A Mavroeidi, J Burghofer, S Kalbourtzis, et al.
ESMO Open|January 9, 2024
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter studyJ Keyl, A Bucher, F Jungmann, et al.
Journal of Clinical Microbiology|April 4, 2000
Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzerG T Maine, R Stricker, M Schuler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)N Frost, M Joosten, J Franzen, et al.
Journal of Child Neurology|March 21, 2012
Consensus statement on standard of care for congenital myopathiesChing H Wang, James J Dowling, Kathryn North, et al.
Journal of Child Neurology|November 17, 2010
Consensus statement on standard of care for congenital muscular dystrophiesChing H Wang, Carsten G Bonnemann, Anne Rutkowski, et al.
Pageof 26